COVID-19 fundings COVID-19 fundings still possible.
1 hour ago:
The study was published today in THE LANCET:
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00393-6/fulltext
« Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19 : a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial ».
In the wake of massive investments to fight the pandemic, Immune Biosolutions received financial support of $4.5M from the Government of Quebec and $13.44M from the Government of Canada. Private investors also injected nearly $5 million into the adventure.
For the rest, the company says it is in negotiations with potential partners for a phase 3 study. The challenge is to find the necessary resources for large-scale production to better assess all the effects and risks associated with treatment on a larger pool of patients.